Quantcast

Latest Prostate cancer Stories

2014-05-29 08:29:37

New Data Presented at ASCO® Annual Meeting Suggest that Genomic Health's Oncotype DX Test May Help Identify Patients That Have the Greatest Opportunity to Benefit from Extended Hormonal Therapy REDWOOD CITY, Calif., May 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of a large, positive study that confirmed that the Oncotype DX® test results for Recurrence Score® and quantitative estrogen-receptor (ER) predict late distant recurrence risk in...

2014-05-29 08:27:06

2014 Public Service Announcement Once Again Rallies the Public to Help Raise Funds for Prostate Cancer Research LOS ANGELES and NEW YORK, May 29, 2014 /PRNewswire-USNewswire/ -- The Safeway Foundation and Stand Up To Cancer (SU2C), a program of the Entertainment Industry Foundation (EIF), have collaborated again to re-launch their public service campaign featuring actress and SU2C Celebrity Ambassador Marcia Cross, which will debut in June....

2014-05-29 04:21:52

ROCKLAND, Massachusetts, May 29, 2014 /PRNewswire/ -- ASCO abstract #: Anti-PD-L1: 3064; c-Met: 2521, TPS4151, TPS8121; tecemotide: TPS3658, TPS7608; TH-302: 8534, 2029; further pipeline: 3551, TPS9107, 5030, 2050, e13552 - Robust pipeline reflects commitment to innovation in oncology and immuno-oncology - Data from nine EMD Serono pipeline products across oncology and immuno-oncology to be presented, including anti-PD-L1, c-Met...

2014-05-28 20:22:42

Natesto(TM) is the first nasal testosterone replacement therapy approved by FDA TORONTO, May 28, 2014 /CNW/ - Trimel Pharmaceuticals Corporation (TSX: TRL) announced today that the United States Food and Drug Administration (FDA) has approved Natesto(TM) (testosterone), formerly CompleoTRT(TM), the first and only testosterone nasal gel for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Natesto(TM) is...

2014-05-28 16:26:55

Educational and Awareness Raising Events Scheduled throughout the Month of June NEW YORK, May 28, 2014 /PRNewswire/ -- The Cancer Research Institute (CRI) is pleased to host its second annual Cancer Immunotherapy Month in June, aimed at increasing awareness of cancer immunotherapy, also known as immuno-oncology, a class of cancer treatment that mobilizes the immune system to fight the disease. Immunotherapy was named Science magazine's 2013 Breakthrough of the Year, and is anticipated once...

2014-05-28 12:30:26

Surveyed U.S. Payers Are Most Receptive to Therapies Offering a Median Overall Survival Benefit over Current Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., May 28, 2014 /PRNewswire/ -- Decision Resources Group finds that, in addition to an improvement in median overall survival (MOS), delayed disease progression is one of the greatest unmet needs in the first-line treatment of chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC). In this...

2014-05-28 04:24:16

Canadians need to protect themselves more from dangerous ultraviolet rays TORONTO, May 28, 2014 /CNW/ - Melanoma skin cancer is one of the fastest rising of all cancers in Canada; Canadians need to do more to protect themselves from damaging ultraviolet (UV) radiation, according to a special report on skin cancer. Canadian Cancer Statistics 2014 was released today by the Canadian Cancer Society in partnership with the Public Health Agency of Canada and Statistics Canada. Skin...

2014-05-27 23:03:55

Humility of Mary Health Partners will provide free PSA blood draws to check 100 men for prostate cancer during the Fuel the Fight car and motorcycle show June 1 at Boardman High School. Youngstown, Ohio (PRWEB) May 27, 2014 Humility of Mary Health Partners will provide 100 free PSA blood draws to check for prostate cancer during the Fuel the Fight car and motorcycle show June 1 in Boardman. Fuel the Fight, sponsored by the HMHP Foundation and Sweeney Chevrolet, Buick, GMC, benefits Man Up...

2014-05-27 16:25:20

-Files patents on markers- TEL AVIV, Israel, May 27, 2014 /PRNewswire/ -- BioLight Life Sciences Investments Ltd. (OTC: BLGTY, TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announced today that Micromedic Technologies (TASE: MCTC), BioLight's cancer diagnostic cluster company, has identified several new genetic markers with high potential to predict necrosis of the jawbone in multiple...

2014-05-27 12:32:49

BETHESDA, Md., May 27, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio) announced today that the Company will host a conference call and webcast with CEO Linda Powers today, May 27, 2014, at 4:30 p.m. Eastern time to review the early results of the Phase I/II DCVax®-Direct Trial announced this morning and answer questions. http://photos.prnewswire.com/prnvar/20110329/SF73084LOGO Participants must register in order to participate in the conference call. There are...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'